Deadline for pre-proposals: Monday, April 29, 2019
UC San Diego Altman Clinical and Translational Research Institute (ACTRI) and Pfizer's Center for Therapeutic Innovation (CTI) are seeking pre-proposals from UC San Diego Health Sciences faculty interested in a drug discovery collaboration with the Pfizer CTI. Proposals are sought for biotherapeutic and small-molecule targets.
Prior to submitting a pre-proposal, investigators are encouraged to meet with Dr. Mary Faris, Senior Director, ES&I, Pfizer, to discuss their projects for suitability for the drug discovery partnership.
CTI Looks for projects geared to drug discovery efforts with the following characteristics:
- Strong project rationale, demonstrated association between target biology and disease mechanism
- Novel drug targets with potential to lead to differentiated drugs
- Link between target pathway and human disease
- Ability to address unmet medical needs
- Feasibility: tractable target, potential for discovery/development plan
- Large Molecules: antibodies, proteins, fusion proteins, antibody conjugates, conditional activated biotherapeutics for enhanced tissue/tumor targeting
- Small Molecules: target classes include kinases, deubiquitinating enzymes, GPCRs, ion channels, solute transporters, epigenetic targets, phosphatases, and RNA modulators
Areas of Interest:
- Cancer – select solid tumors: colorectal, breast, lung, prostate, pancreatic, hepatocellular, ovarian cancers.
- Autoimmunity/Inflammation – inflammatory bowel disease, Non-alcoholic fatty liver disease/Non-alcoholic steatohepatitis, atopic dermatitis, psoriasis, Rheumatoid arthritis.
- Metabolic – cardiometabolism, cachexia.
- Rare – monogenic hematologic (non-malignant) disorders, neurologic/neuromuscular disorders, inborn errors of metabolism, endocrine, renal and cardiovascular diseases. Ultra-rare indications are not in scope at this time.
- DNA damage recognition and repair (e.g. replication stress or repair mechanisms)
- Tissue–resident immune modulation (e.g. adaptive or innate mechanisms, immunometabolism, etc.)
- Immune activators /enhancers (e.g. nucleic acid sensing, toll-like receptors etc)
- Modulation of senescence in cancer and non-neoplastic indications
- DNA repeat expansion diseases (e.g. Huntington’s disease, amyotrophic lateral sclerosis, myotonic dystrophy or frontotemporal dementia)
- Regulation of epithelial or mucosal barrier function including autophagy, host-microbe interactions
- Modulation of fibrosis pathways, either metabolism/stress-induced or inflammation-induced (possibly tumor-driven)
- Regulation of antigen-specific immune tolerance induction
- Emerging metabolic regulators in heart failure, satiety, nonalcoholic steatohepatitis and muscle biology
CTI Collaborations may include:
- Funded project-related research
- Hands-on collaboration from dedicated Pfizer drug-development experts
- Access to scientific/technological expertise and infrastructure at Pfizer
- Potential for financial incentives in the form of milestone and royalty payments
- Flexible publishing rights
- Opportunity for involvement in CTI’s Foundation collaborations
Pre-proposal Submission Process
Submission entails a non-confidential 2-3 page overview of the target, mechanism, evidence for disease linkage, and the proposed therapeutic drug. At a high level, the pre-proposal should suggest how the therapeutic hypothesis could be tested in the clinic
All researchers and clinicians whose work meets these criteria are invited to apply. Please submit non-confidential pre-proposals to your Technology Transfer Office by April 29th. For further information about submitting a pre-proposal, please contact Eric Mah.
For further information about areas of focus, please contact Dr. Mary Faris.